62 related articles for article (PubMed ID: 15953192)
21. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
22. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
23. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.
Seymour LW; Ulbrich K; Steyger PS; Brereton M; Subr V; Strohalm J; Duncan R
Br J Cancer; 1994 Oct; 70(4):636-41. PubMed ID: 7917909
[TBL] [Abstract][Full Text] [Related]
24. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
Greco F; Vicent MJ; Gee S; Jones AT; Gee J; Nicholson RI; Duncan R
J Control Release; 2007 Jan; 117(1):28-39. PubMed ID: 17129632
[TBL] [Abstract][Full Text] [Related]
25. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells.
Malugin A; Kopecková P; Kopecek J
J Control Release; 2007 Dec; 124(1-2):6-10. PubMed ID: 17869367
[TBL] [Abstract][Full Text] [Related]
26. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.
Kovár M; Kovár L; Subr V; Etrych T; Ulbrich K; Mrkvan T; Loucká J; Ríhová B
J Control Release; 2004 Sep; 99(2):301-14. PubMed ID: 15380639
[TBL] [Abstract][Full Text] [Related]
27. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems.
Lammers T; Peschke P; Kühnlein R; Subr V; Ulbrich K; Debus J; Huber P; Hennink W; Storm G
J Control Release; 2007 Feb; 117(3):333-41. PubMed ID: 17215057
[TBL] [Abstract][Full Text] [Related]
28. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657
[TBL] [Abstract][Full Text] [Related]
29. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.
Kovar M; Tomala J; Chmelova H; Kovar L; Mrkvan T; Joskova R; Zakostelska Z; Etrych T; Strohalm J; Ulbrich K; Sirova M; Rihova B
Cancer Res; 2008 Dec; 68(23):9875-83. PubMed ID: 19047168
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma.
Říhová B; Etrych T; Šírová M; Tomala J; Ulbrich K; Kovář M
J Drug Target; 2011 Dec; 19(10):890-9. PubMed ID: 21981636
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
33. Designing polymer conjugates as lysosomotropic nanomedicines.
Duncan R
Biochem Soc Trans; 2007 Feb; 35(Pt 1):56-60. PubMed ID: 17233601
[TBL] [Abstract][Full Text] [Related]
34. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
35. pH-responsive PDMS-b-PDMAEMA micelles for intracellular anticancer drug delivery.
Car A; Baumann P; Duskey JT; Chami M; Bruns N; Meier W
Biomacromolecules; 2014 Sep; 15(9):3235-45. PubMed ID: 25068477
[TBL] [Abstract][Full Text] [Related]
36. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
37. Differences in the intracellular fate of free and polymer-bound doxorubicin.
Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics.
Ríhová B; Kovár L; Kovár M; Hovorka O
Trends Biotechnol; 2009 Jan; 27(1):11-7. PubMed ID: 19022512
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy Towards Cancer-A Perspective.
Kitson SL; Cuccurullo V; Ciarmiello A; Mansi L
Anticancer Agents Med Chem; 2017; 17(3):311-317. PubMed ID: 27671296
[TBL] [Abstract][Full Text] [Related]
40. Metastatic spread inhibition of cancer cells through stimuli-sensitive HPMA copolymer-bound actinonin nanomedicines.
Kousalová J; Šírová M; Kostka L; Šubr V; Kovářová J; Běhalová K; Studenovský M; Kovář M; Etrych T
Nanomedicine; 2022 Aug; 44():102578. PubMed ID: 35779856
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
